LNLingling Neng

Lingling Neng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lingling Neng has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adenosine Acts Through A2AR to Alleviate the Inflammatory Response Caused by Activation of Perivascular-Resident Macrophage-Like Melanocytes

    by Wenya Fan, Jiale Lv, Lingling Neng, Bin Zuo, Zhanjiang Xu, Bei Chen, Jinhui Zhang

    Background: Disruption of the blood labyrinth barrier (BLB) is considered a pathological cause of diverse hearing impairments. Perivascular-resident macrophage-like melanocytes (PVM/Ms) play a critical role in maintaining inner ear homeostasis and BLB integrity. Activation of PVM/Ms leads to decreased production of pigment epithelium-derived factor (PEDF), contributing to BLB breakdown. This study investigated the role of the adenosine A2A receptor (A2AR) pathway in lipopolysaccharide (LPS)-induced inflammation in PVM/Ms and elucidated the underlying mechanisms. Methods: The anti-inflammatory effects of adenosine and its specific receptor A2AR were evaluated in LPS-induced PVM/Ms. The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) were measured by quantitative real-time PCR (qRT-PCR) and enzyme linked immunosorbent assay (ELISA). Additionally, matrix metalloproteinase-9 (MMP-9) and PEDF were quantified using western blot and ELISA, respectively. An endothelial cell (EC)-PVM/M co-culture model exposed to LPS was established and treated with adenosine and SCH58261 to assess effects on BLB permeability. Results: LPS treatment significantly changed the production of inflammatory factors, including IL-6 and TNF-α, as well as MMP-9, TIMP-1, and PEDF. These changes were abrogated by adenosine, which also reduced the production of reactive oxygen species (ROS) and inhibited the activation of PVM/Ms. SCH58261 partially reversed the effects of adenosine following LPS treatment. The p38 MAPK pathway was found to be involved in adenosine regulation of LPS-induced PVM/Ms. Conclusions: Adenosine attenuates the inflammatory activation of PVM/Ms and enhances their ability to maintain endothelial barrier integrity by binding to A2AR. The findings support adenosine and A2AR as potential therapeutic targets for treating hearing impairments.


  • Open Access

    VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

    by Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, et al.

    Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.


  • Open Access

    Missense Variant of Endoplasmic Reticulum Region of WFS1 Gene Causes Autosomal Dominant Hearing Loss without Syndromic Phenotype

    by Jinying Li, Hongen Xu, Jianfeng Sun, Yongan Tian, Danhua Liu, Yaping Qin, Huanfei Liu, Ruijun Li, Lingling Neng, Xiaohua Deng, et al.

    Objective. Genetic variants in the WFS1 gene can cause Wolfram syndrome (WS) or autosomal dominant nonsyndromic low‐frequency hearing loss (HL). This study is aimed at investigating the molecular basis of HL in an affected Chinese family and the genotype‐phenotype correlation of WFS1 variants. Methods. The clinical phenotype of the five‐generation Chinese family was characterized using audiological examinations and pedigree analysis. Target exome sequencing of 129 known deafness genes and bioinformatics analysis were performed among six patients and four normal subjects to screen suspected pathogenic variants. We built a complete WFS1 protein model to assess the potential effects of the variant on protein structure. Results. A novel heterozygous pathogenic variant NM_006005.3 c.2020G>T (p.Gly674Trp) was identified in the WFS1 gene, located in the C‐terminal domain of the wolframin protein. We further showed that HL‐related WFS1 missense variants were mainly concentrated in the endoplasmic reticulum (ER) domain. In contrast, WS‐related missense variants are randomly distributed throughout the protein. Conclusions. In this family, we identified a novel variant p.Gly674Trp of WFS1 as the primary pathogenic variant causing the low‐frequency sensorineural HL, enriching the mutational spectrum of the WFS1 gene.